What the July 23–24 PCAC Meeting Will Actually Decide

The Pharmacy Compounding Advisory Committee (PCAC) will meet on July 23 and 24 to recommend final 503A Bulks List placement for the twelve peptides the FDA reclassified on April 15. The committee is a 13-member advisory panel of pharmacists, physicians, and public members. Its recommendations are advisory, not binding — but the FDA has historically adopted PCAC recommendations with high fidelity.

There are three outcomes possible for each of the twelve peptides, and the committee will address them individually:

Full approval places the peptide on the 503A Bulks List without conditions. Licensed compounding pharmacies may prepare it under patient-specific prescriptions nationwide, subject only to standard state pharmacy board rules. This is the likely outcome for peptides with the strongest safety profiles and clearest use cases — BPC-157, TB-500, GHK-Cu, KPV, and MOTS-c are the most frequently cited candidates among industry observers.

Approval with restrictions places the peptide on the list with specific conditions — narrower indication lists, restricted routes of administration, or specific prescriber credentials. KPV and LL-37 are possible candidates here given the narrowness of their strongest-evidence use cases.

Referred for further study delays the decision, typically pending additional toxicology or clinical data submission. For peptides in this category, legal compounding access remains in the interim evaluation tier during the study period, which can last six to eighteen months. Melanotan II and Dihexa are the most frequently mentioned candidates for deferral, reflecting the former’s adverse-event history and the latter’s sparse human data.

A fourth outcome — outright rejection, returning a peptide to the prohibited Category 1 — is considered unlikely across the board absent new safety signals surfacing before the meeting.

The public comment period is open. Any party may submit a written comment through the Federal Register docket, which will be posted approximately 30 days before the meeting at regulations.gov. Comments from clinicians and patients with direct experience carry the most procedural weight.

For subscribers who want to follow the PCAC meeting in real time, the PeptidesBeat daily brief will cover the meeting live and publish a full post-decision briefing within 72 hours.